Johnson & Johnson will stop selling talc-based baby powder globally in 2023, the drugmaker said on Thursday, more than two years after it ended U.S. sales of a product that drew thousands of consumer safety lawsuits.
If you are not happy with the results below please do another search
50 search results for:
Xofluza is the first and only single-dose oral medicine for the treatment of influenza to be approved in the United States for children as young as five years of age. The FDA also approved the drug to prevent influenza in children aged five years and older following contact with an infected person.
The two fatal cases of acute liver failure took place in Russia and Kazakhstan after 5 to 6 weeks of Zolgensma infusion and about 1-10 days following the initiation of corticosteroid taper, according to the company.
Greater Than One, a privately held agency focused on healthcare, announced that Mindy Telmer has been appointed executive creative director, EVP. Telmer will be the creative voice of the agency, responsible for providing Greater Than One clients with strategic creative direction and oversight from inception through execution. Telmer will report directly to Matthew Howes, president of Greater Than One.
While the economy expands and contracts, the biopharma industry follows, and many life science companies are announcing both layoffs and expansions.
Bioduro-Sundia operates in the United States and China, with more than 2,000 employees and 10 facilities, providing contract research, development and manufacturing outsourcing services.
Panacell Biotech plans to initiate a program to investigate the use of natural killer (NK) immune cells, exosomes and brown adipose-derived stem cells to treat Long COVID.
MaaT Pharma announced that the U.S. FDA has maintained the clinical hold on MaaT013, its candidate for patients with steroid-resistant acute graft-versus-host disease.
Spain has asked the European Medicines Agency (EMA) for permission to give more people a smaller dose of monkeypox vaccine, an approach known as “dose sparing” to distribute limited supplies as far as possible, the health ministry said.
Shares in GSK, Sanofi and Haleon fell sharply on Thursday, following declines earlier this week, amid growing concerns about U.S. litigation over a heartburn drug that was pulled from the market in 2020 for containing a probable carcinogen.